Cargando…

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy

Programmed cell death ligand 1 (PD-L1) expression remains the most widely used biomarker for predicting response to immune checkpoint inhibitors (ICI), but its predictiveness varies considerably. Identification of factors accounting for the varying PD-L1 performance is urgently needed. Here, using d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Anlin, Luo, Linfeng, Du, Wei, Yu, Zhixin, He, Lina, Fu, Sha, Wang, Yuanyuan, Zhou, Yixin, Yang, Chunlong, Yang, Yunpeng, Fang, Wenfeng, Zhang, Li, Hong, Shaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495439/ https://www.ncbi.nlm.nih.gov/pubmed/37696887 http://dx.doi.org/10.1038/s41698-023-00443-3

Ejemplares similares

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
por: Luo, Linfeng, et al.
Publicado: (2023)

Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer
por: Wang, Yixing, et al.
Publicado: (2023)

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy
por: He, Li-Na, et al.
Publicado: (2023)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy
por: He, Li-na, et al.
Publicado: (2021)

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma
por: Chen, Chen, et al.
Publicado: (2020)

Pretreatment Serum Lactate Dehydrogenase and Metastases Numbers as Potential Determinants of Anti-PD-1 Therapy Outcome in Nasopharyngeal Carcinoma
por: Ali, Wael A. S., et al.
Publicado: (2023)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles
por: Yang, Zhi, et al.
Publicado: (2017)

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
por: Zhang, Xuanye, et al.
Publicado: (2019)

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis
por: Zhou, Yixin, et al.
Publicado: (2018)

Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy
por: Wang, Yixing, et al.
Publicado: (2021)

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival
por: Fang, Wenfeng, et al.
Publicado: (2015)

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
por: Yang, Yuanyuan, et al.
Publicado: (2022)

Deciphering the role of QPCTL in glioma progression and cancer immunotherapy
por: Liu, Yu’e, et al.
Publicado: (2023)

A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment
por: Jiang, Yongluo, et al.
Publicado: (2022)

Combinatorial assessment of ctDNA release and mutational burden predicts anti‐PD(L)1 therapy outcome in nonsmall‐cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2020)

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China
por: Yang, Yunpeng, et al.
Publicado: (2016)

Generative pretraining from large-scale transcriptomes for single-cell deciphering
por: Shen, Hongru, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Metabolomics Coupled with Transcriptomics Approach Deciphering Age Relevance in Sepsis
por: Xu, Dingqiao, et al.
Publicado: (2019)

Deciphering the potential roles of ferroptosis in regulating tumor immunity and tumor immunotherapy
por: Gu, Xu, et al.
Publicado: (2023)

Deciphering the transcriptomic signature of synaptic activity
por: Hermey, Guido
Publicado: (2021)

Co‐delivery of dendritic cell vaccine and anti‐PD‐1 antibody with cryomicroneedles for combinational immunotherapy
por: Chang, Hao, et al.
Publicado: (2022)

Cancer biology deciphered by single-cell transcriptomic sequencing
por: Li, Yanmeng, et al.
Publicado: (2021)

A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
por: Ma, Yuxiang, et al.
Publicado: (2019)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma
por: Zhang, Xuanye, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy
por: Alam, Md Rakibul, et al.
Publicado: (2023)

Divergence and Convergence of Cerebral Ischemia Pathways Profile Deciphers Differential Pure Additive and Synergistic Mechanisms
por: Wei, Penglu, et al.
Publicado: (2020)

EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Deciphering the porcine intestinal microRNA transcriptome
por: Sharbati, Soroush, et al.
Publicado: (2010)

Deciphering the Developmental Dynamics of the Mouse Liver Transcriptome
por: Gunewardena, Sumedha S., et al.
Publicado: (2015)

Deciphering a mitochondria-related signature to supervise prognosis and immunotherapy in hepatocellular carcinoma
por: Shi, Yanlong, et al.
Publicado: (2022)

Deciphering the role of NETosis-related signatures in the prognosis and immunotherapy of soft-tissue sarcoma using machine learning
por: Qi, Lin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_05gnti56isf7ddmceh44vdn0dr